The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
CMS Reins in Spending Under 340B, Garnering Praise, Criticism
November 2nd 2017A newly announced CMS policy to redistribute savings under the 340B Drug Discount Program so that Medicare beneficiaries save money on copayments has garnered a mixture of praise and criticism from supporters and critics of the program.
NICE Recommends Frontline Atezolizumab for Advanced Urothelial Cancer
November 2nd 2017The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.
Expert Expands on Decision-Making Impact of Genetic Testing in Breast Cancer
November 1st 2017Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.
Novartis Submits sBLA for Tisagenlecleucel in Adults With Relapsed/Refractory DLBCL
October 31st 2017Novartis has filed a supplemental biologics license application with the FDA to expand the indication for tisagenlecleucel (Kymriah) to include adults with relapsed/refractory DLBCL who are ineligible for ASCT.
Merck Withdraws EU Application for Frontline Pembrolizumab Combo in NSCLC
October 30th 2017Merck has announced that it has withdrawn its European application for pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer.
Individualized Adjuvant Endocrine Approach Appropriate in Breast Cancer
October 25th 2017Ten-year results from the TEAM trial on exemestane alone and sequential treatment with tamoxifen followed by exemestane for postmenopausal women with hormone receptor-positive breast cancer showed they were reasonable treatment options.
No Benefit With Prolonged Native E. Coli Asparaginase in Pediatric ALL, NHL
October 25th 2017Treatment with prolonged native E. coli asparaginase therapy for children with acute lymphoblastic leukemia or non-Hodgkin lymphoma not only failed to improve survival versus the standard regimen, but also resulted in an increase in infections and allergy.